@dansfera: Yikes! Navigating the biotech landscape is never simple, is it? 🤔 This deep dive uncovers the major friction points for one particular stock. Phase 3 is widening the net to a broader, less optimized patient pool, trying to mirror real-world conditions—but the confirmatory cohort still delivered solid numbers (82% ORR & 51% PFS!). However, that at-the-market offering at $1.90 is raising eyebrows; capital raised *before* the anticipated re-rate spells dilution danger. Plus, the competition is fierce, with Allogene's CIMA cell also targeting that hot CD19 space! Investor beware! 🔥 #BiotechInvesting #StockMarket #Pharma #InvestmentHurdles #CD19

dansfera

Open In TikTok:

Region: US

Tuesday 03 March 2026 20:09:29 GMT